<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456232</url>
  </required_header>
  <id_info>
    <org_study_id>GDREC2017324H</org_study_id>
    <nct_id>NCT03456232</nct_id>
  </id_info>
  <brief_title>High-flux Hemodialysis Versus Hemodiafiltration for End-Stage Renal Disease</brief_title>
  <official_title>High-flux Hemodialysis Versus Hemodiafiltration for End-Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of high-flux hemodialysis compared to hemodiafiltration on
      small and moderate molecule substances clearance. Meanwhile, this study evaluates the effect
      of high-flux hemodialysis compared to hemodiafiltration on cardiac function. In this self
      matching study, participants will receive high-flux hemodialysis compared to
      hemodiafiltration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful
      substances in the blood and excessive water, is one of the most commonly replacement therapy.

      Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of
      treatment advantages, both by diffusion and convection principle to remove harmful substances
      in the blood.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">March 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of moderate molecule substance</measure>
    <time_frame>4 hours after dialysis</time_frame>
    <description>Clearance rate of b2-microglobulin for one dialysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>4 hours after dialysis</time_frame>
    <description>Left ventricular ejection fraction is calculated by dividing the volume of blood pumped from the left ventricle per beat, also known as stroke volume, by the end-diastolic volume.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>High-flux hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-flux hemodialysis lasting for 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodiafiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemodiafiltration lasting for 4 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-flux hemodialysis</intervention_name>
    <description>High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.</description>
    <arm_group_label>High-flux hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hemodiafiltration</intervention_name>
    <description>Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.</description>
    <arm_group_label>Hemodiafiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has end-stage renal disease.

          2. Subject has been on regular dialysis treatment for at least 6 months.

          3. Subject has autologous vascular access.

          4. Subject is offered thrice weekly hemodialysis.

          5. Subject is offered 4 hours duration hemodialysis.

        Exclusion Criteria:

          1. Infectious disease

          2. Poor echocardiographic window that was unsuitable for interpretation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Shi, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Li, Master</last_name>
    <phone>＋86-20-81346722</phone>
    <email>13580588265@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wei shi, MD,PhD</last_name>
      <phone>＋86-20-83850849</phone>
      <email>13925056339@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Li, Master</last_name>
      <phone>＋86-20-81346722</phone>
      <email>13580588265@139.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yi Li, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuangxin Liu, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianchao Ma, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lixia Xu, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuanhan Chen, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Lin, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>hemodiafiltration</keyword>
  <keyword>end-stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Supporting Information: study protocol, statistic analysis plan, informed consent form, clinical study report.
Time Frame: Data will be available within 1 year of study completion. Access Criteria: Data access requests will be reviewed by an external Independent Review panel. Requestors will be required to sign a Data Access Agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

